What makes an academic asset collaboration-ready for Pharma nowadays?

Pharma companies, one of the leading stakeholders of life sciences innovation, keep adapting to the evolution of the sector and the collaborations they can build according to internal strategies, pipelines and potential assets emerging from academia and young companies. With M&A activity picking up again in 2025, 25% of the deals related to early-stage assets, or else the popularity of the venture builder model, signals are here showing that the early-stage playground remains attractive to Pharma. What are big companies expecting these days to consider opening the discussion to collaboration? Speakers will bring insightful advice and perspective, from the level of data readiness, to the component of a strong team, as well as roadmaps, target product profiles…